The person who says something is impossible
should not interrupt the person who is doing it
.” 

—Chinese proverb

Portfolio

 

 Current:  
  

Armetheon

About: Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) drugs that are direct inhibitors of thrombin or Factor Xa, tecarfarin could be used in patients with (i) prosthetic heart valves, and/or (ii) who have renal dysfunction (with one Phase III completed). The second drug candidate under development is budiodarone which is an oral Phase 2 clinical-stage drug candidate that is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs) and for the treatment of patients with refractory atrial fibrilation. Planning to grow the company over time with additional pipeline. www.armetheon.com

Founded: October, 2011 (Sunnyvale, CA)
Total funds raised; $33 MM
Other Investors: Capital TEN II, Hercules Bioventures, CDIB
 Healthcare, CDIB & Partners, AshHill Biomedical Investments, iD SoftCapital, AmKey Ventures, Lee’s Pharmaceutical (Hong Kong) and eminent biotech entrepreneurs and pharmaceutical executives.

  

 renexxion logo

About: Renexxion* is a pharmaceutical company developing potentially a best-in-class safe and effective 5HT4 agonist, naronapride, for gastrointestinal (GI) disorders. The company has adopted a pipeline-in-a-pill strategy. Phase 3 ready naronapride has successfully completed several Phase-2 clinical trials for the treatment of multiple gastrointestinal disorders including CIC, GERD, and functional dyspepsia. The FDA DGIEP now has agreed formally to a rapid and low-risk pathway to approval in chronic idiopathic constipation (CIC) that does not require extensive cardiovascular safety testing. In addition to the chronic oral formulation enabled by the recent FDA interaction, an intravenous formulation (or single use oral solution formulation) can be developed for the growing and important unmet needs in ICU and ventilator units of enteral feeding intolerance (EFI), acute GP, short bowel syndrome (SBS) and postoperative ileus (POI). Today there are currently no FDA-approved treatment options available and these acute care indications impact several millions of Americans with EFI alone affecting one million Americans.  www.renexxion.com

Founded: September, 2014 (Menlo Park, CA)
Total funds raised: Not Disclosed
Other Investors:
 Founders and angel investors

  
Past:  

 

About: Altheos, Inc. was focused on developing novel ophthalmic drugs for unmet clinical need in glaucoma.

Founded: April, 2009 (South San Francisco, CA)
Total funds raised; $32.5MM
Investors: Bay City Capital, Canaan Partners, Novo, Life Science Angels, angel investors and founders

 

 Comentis About: Athenagen (later renamed CoMentis)* is dedicated to the discovery and development of small-molecule drugs to treat Alzheimer’s disease.

Founded: April, 2005 (renamed CoMentis following merger with Zapaq, Inc. in 2007) (South San Francisco, CA)
Total funds raised; $87 MM
Other Investors: Sanderling Ventures, Clarus Ventures, Index ventures, Charter Life Sciences, Astellas Pharma, Inc. and Astellas Venture Capital LLC

 

*previously funded/separately funded and currently managed on behalf of general partner

“So many of our dreams at first seem impossible, then they seem improbable, and then, when we summon the will, they soon become inevitable.” - Christopher Reeve